PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM

BACKGROUND: The PI3K pathway is activated in most GBMs and represents a potential therapeutic target. Buparlisib is an oral, pan-Class I PI3K inhibitor that enters the brain at therapeutic concentrations and inhibits the growth of U87 and human glioma tumor sphere models. METHODS: The Ivy Consortium...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wen, Patrick Y., Yung, W. K. Alfred, Mellinghoff, Ingo K., Ramkissoon, Shakti, Alexander, Brian, Rinne, Mikael, Colman, Howard, Omuro, Antonio M., DeAngelis, Lisa M., Gilbert, Mark R., DeGroot, John, Cloughesy, Timothy F., Lee, Eudocia Q., Nayak, Lakshmi, Chi, Andrew S., Batchelor, Tracy, Chang, Susan M., Prados, Michael D., Reardon, David A., Ligon, Keith L.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144634/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou209.20
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars